An expandable vaginal dilator includes a stretchable sheath defining at least one fluid chamber therein and being shaped and sized according to vaginal measurements and physical examination. A support within the sheath seals and holds the sheath and provides one or more fluid channels configured for delivery of fluid into the at least one fluid chamber to expand the sheath. The support is configured to permit vaginal insertion of the sheath when the sheath is in an unexpanded state and to stabilize the sheath during expansion of the sheath. One or both of the sheath and support can be sized and shaped according to the physical exam of a patient. One or both of the sheath and support can be configured to provide differential expansion according to the physical patient information and a treatment plan.
A method for producing one or more hydroxide solids includes providing a catholyte comprising an electrolyte solution; contacting the catholyte with an electroactive mesh cathode to electrolytically generate hydroxide ions, thereby precipitating the one or more hydroxide solid(s); and removing the one or more hydroxide solids from the surface of the mesh where they may deposit.
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. - GENERAL VER-WALTUNG (Germany)
CHARITE - UNIVERSITATSMEDIZIN BERLIN (Germany)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
Grosswendt, Stefanie
Meissner, Alexander
Christaller, Tobias
Stachel-Braum, Philipp
Gartner, Zev
Moser, Brittany
Chow, Eric
Abstract
The present invention provides a method for obtaining sequencing-based information from cells/nuclei, the method comprising (a) a first barcoding of cells and/or nuclei of a group of cells and/or nuclei comprising interacting cells with one or more group-specific barcode sequence(s) or a group-specific combination of one or more barcode sequence(s); (b) a second barcoding of nucleic acid molecules contained in and/or attached to individual cells and/or nuclei from said group of cells/nuclei with a cell/nucleus-specific barcode sequence; and (c) sequencing of the barcoded nucleic acid sequences.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Koskella, Britt
Lin, Henry C.
Lin, Derek M.
Abstract
A bacteriophage preparation generally includes a preparation of a heterogeneous bacteriophages obtained from a fermentative process. The bacteriophage preparation may be formulated into a pharmaceutic composition. The bacteriophage preparation may be used to treat dysbiosis by administering the bacteriophage preparation to a subject having, or at risk of having, dysbiosis. The bacteriophage preparation may be used to prepare or prime the gut environment of a healthy subject prior to administering a source of bacteria to the subject.
Provided herein are methods and compositions for the treatment of ALS using chlorite or a pharmaceutical composition comprising sodium chlorite, for a target ALS patient population. Also provided herein are methods for identifying a target ALS patient population likely to be responsive to treatment with chlorite or a pharmaceutical composition comprising sodium chlorite, the methods including identifying ALS patients with elevated plasma C-reactive protein (CRP) levels and/or patients age 40-65, sporadic ALS pathology, or combinations thereof.
The instant disclosure teaches a highly efficient cellulose-based nanoadsorbent that can capture more than 6000 mg of doxorubicin (DOX), one of the most widely used chemotherapy drugs, per gram of the adsorbent at physiological conditions. Such drug capture capacity is more than 3200% higher than other nanoadsorbents, such as DNA-based platforms. The disclosure teaches how anionic hairy cellulose nanocrystals, also known as electrosterically stabilized nanocrystalline cellulose (ENCC), bind to positively charged drugs in human serum and capture DOX immediately without imposing any cytotoxicity and hemolytic effects. The disclosure further elucidates how ENCC provides a remarkable platform for biodetoxification at varying pH, ionic strength, ion type, and protein concentration. These discoveries pave the way for the next generation in vitro and in vivo drug capture additives and devices.
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
8.
MICROFLUIDIC SYSTEM FOR RAPID FLUID VISCOSITY MEASUREMENT USING ACOUSTIC MICROSTREAMING
The present invention is directed to devices that ailow for measurement of molecule/particle viscosity. The present invention features a microfluidic platform for measuring fluid viscosity. In some embodiments, the microfluidic platform may comprise a main chamber and one or more cavity acoustic transducers (CATs). The microfluidic platform may further comprise an external acoustic source coupled to the main chamber. The microfluidic platform may further comprise a fluid disposed into the main chamber. Said fluid may comprise one or more beads. The fluid may intersect the CATs to form one or more interfaces. The CATs may be configured to oscillate the interfaces to generate microstreaming flow patterns trapping the one or more beads therein. A viscosity of the fluid can be derived from the velocity.
G01N 11/10 - Investigating flow properties of materials, e.g. viscosity or plasticity; Analysing materials by determining flow properties by moving a body within the material
G01N 9/34 - Investigating density or specific gravity of materials; Analysing materials by determining density or specific gravity by using flow properties of fluids, e.g. flow through tubes or apertures by using elements moving through the fluid, e.g. vane
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
10.
NOVEL WNT AGONIST ANTIBODIES AND THERAPEUTIC USES THEREOF
Antibodies are provided herein that agonize Wnt signaling, do not compete with a Wnt ligand for LRP6 binding, and activate Wnt signaling in the presence of inhibitors. Methods for promoting cell differentiation and tissue regeneration using the disclosed antibodies are also provided.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Methods and compositions are provided for enhancing endoplasmic reticulum-associated degradation (ERAD) and suppressing pathological accumulation of misfolded proteins in cells by increasing expression or activity of zinc transporter protein 7 (ZIP7). Methods of treating a subject for a disorder associated with protein misfolding are also provided, including methods of gene therapy for expressing ZIP7 in vivo in effective amounts sufficient to suppress pathological accumulation of misfolded proteins.
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A cathode for a high voltage lithium-ion secondary battery is described, including: an electrode layer having an electrode composition containing cathode active particles, fluoropolymer binder and conductive carbon. The cathode active particles are high voltage lithium transition metal oxides, the fluoropolymer binder is a fibrillated tetrafluoroethylene polymer having high melt creep viscosity, and the conductive carbon is carbon fibers having a specific surface area of about 50 m2/g or less. The carbon fibers and the fluoropolymer binder form a conducting structural web electronically connecting the cathode active particles, enabling electronic conductivity through the electrode layer. The electrode layer is adhered to a current collector comprising aluminum having surface roughness and substantially no carbon surface coating other than the conductive carbon of the electrode layer. Further described is a dry binder process to fabricate such cathodes, and the utility of such cathodes in high voltage lithium-ion secondary batteries.
H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/136 - Electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
H01M 4/1397 - Processes of manufacture of electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
H01M 10/0569 - Liquid materials characterised by the solvents
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
The invention provides improved insecticide compositions comprising an insecticide and an arthropod repellent, an optional solvent, and/or their ingredients. The present invention also includes compositions methods of killing the insects.
A01N 31/16 - Oxygen or sulfur directly attached to an aromatic ring system with two or more oxygen or sulfur atoms directly attached to the same aromatic ring system
A01N 65/24 - Lauraceae [Laurel family], e.g. laurel, avocado, sassafras, cinnamon or camphor
A01N 37/10 - Aromatic or araliphatic carboxylic acids, or thio-analogues thereof; Derivatives thereof
A01N 37/18 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imides; Thio-analogues thereof
Disclosed herein are methods and compositions for treatment, prognosis, and diagnosis of cancer, including prostate cancer. Aspects of the disclosure are directed to methods for a subject having prostate cancer determined to have ZNRF3 genomic loss, reduced ZNRF3 expression, and/or increased ZNRF3 methylation. Also disclosed are methods for analysis of tumor DNA for ZNRF3 copy number status, expression, and/or methylation, as well as compositions and kits useful for such analysis.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
Provided herein are, inter alia, antibodies, which bind Related-to-Receptor Tyrosine Kinase (Ryk) with high efficiency and specificity. The antibodies and antibody compositions provided herein include, for example, novel light and heavy chain domain CDRs and framework regions and are, inter alia, useful for diagnosing and treating cancer and other RYK-related diseases. In embodiments, the anti-RYK antibodies provided herein are capable of binding a human RYK protein, but not a mouse RYK protein.
The disclosure provides compositions, preparations, and methods comprising cell- derived vesicles induced using a blebbing agent from a hybridoma of a dendritic cell and a target cell, and uses thereof, including as a means to modulate a subject's immune system.
The disclosure provides for compositions and methods comprising cell-derived vesicles induced from cells that have been genetically engineered or infected to express specific antigen(s), and uses thereof, including as a cell-free, cell-like vaccine.
The present application provides oxazoles-containing compounds, or a pharmaceutically acceptable salt thereof, that are 12/15-LOX inhibitors. Pharmaceutical compositions and methods of using these compounds for treating various conditions wherein 12/15-LOX is implicated (such as stroke) are also provided.
C07D 263/48 - Nitrogen atoms not forming part of a nitro radical
A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/501 - Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Disclosed are devices, systems and methods for neural signal detection of immune responses. In some aspects, a system includes a processing unit; a receiving unit configured to receive at least one sensor signal from a wearable sensor, where the wearable sensor is configured to detect at least one neural signal of a patient; and a tangible non-transitory computer readable medium having instructions configured to cause the processing unit to automatically receive a data signal from the receiving unit, automatically detect an immune response based at least in part on the data signal, automatically create a notification based at least in part on the immune response, and automatically present the notification to a user of the system.
A method for patient stratification may include applying a first machine learning model to determine, based on a clinical data of a patient, a risk score for the patient. Where the risk score for the patient exceeds a threshold, a second machine learning model may be applied to determine a first probability of the risk score being a false positive. Where the risk score for the patient fails to exceed the threshold, a third machine learning model may be to determine a second probability of the risk score being a false negative. Clinical recommendations for the patient may be determined based on the risk score, the first probability of the risk score being the false positive, and the second probability of the risk score being the false negative. Related systems and computer program products are also provided.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The methods and compositions of the disclosure are used to prevent or treat autoimmune diseases and disorders, such as lupus, by administering a PTPRS activating agent. The agent does not deplete pDCs or cause a general blockade of IFN? signaling and therefore is less immunosuppressive and easier to combine with other immunosuppressants.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventor
Nano, Tomi
Capaldi, Dante
Abstract
Methods, systems, and devices, including computer programs encoded on a computer storage medium are provided for measuring and displaying subject motion information during procedures which require remote subject monitoring. The system uses a mobile device with depth sensor capabilities, data processing capabilities and artificial intelligence (AI) predictive models to provide motion information. The system motion information can be used to measure the period of time a subject performed deep-inspiration breath hold (DIBH) and for training the subject to achieve a DIBH of at least 20 seconds.
Disclosed here are devices, systems, and methods for continuous monitoring of biomarkers using a wearable, non-intrusive microneedle sensor patch platform. In some aspects, a wearable, non-intrusive microneedle sensor device includes a microneedle sensor unit couplable to an electronics unit, where the microneedle sensor unit comprises a substrate, an array of spiked microneedle structures configured as electrochemical sensor electrodes, an array of base structures that encase a lower portion of spiked microneedle structures, and electrical interconnections that electrically couple the electrodes to the electronics unit for processing of detectable signals associated with one or multiple biomarkers in a biofluid.
Disclosed herein are methods of capturing CO2 from a gas source using electrochemically-enhanced amine capture to form a concentrated CO2 vapor, followed by sequestering CO2 from the concentrated vapor in a sequestration step. The sequestration step includes contacting the concentrated vapor with an aqueous sequestration solution comprising ions capable of forming an insoluble carbonate salt, such that the aqueous sequestration solution comprises the CO2, electrochemically basifying the sequestration solution, thereby precipitating a carbonate solid, separating the carbonate solids from the aqueous sequestration solution or the surface of the mesh.
B01D 53/14 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
B01D 53/32 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
The present disclosure provides pharmaceutical compositions and drug delivery devices comprising a compound of formula I, II, III, or IV. Methods are provided for inhibiting activity of an E3 ligase, involving contacting the E3 ligase with a compound of formula I, II, III, or IV. The present disclosure provides various treatment methods involving administration of such compounds.
Compositions comprising an antifungal RNA and a lipid vesicle are provided, wherein the antifungal RNA comprises a double-stranded RNA, a small RNA, or a small RNA duplex. The lipid vesicle may be, for example, a plant-derived vesicle or an artificial vesicle containing a tertiary amine cationic lipid. For example, the RNA may target a dicer-like (DCL) gene or a long terminal repeat (LTR) region of a fungal pathogen such as Botrytis or Verticillium. Methods for increasing pathogen resistance in plants are also described.
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
Disclosed are compounds of formula (I): formula (I) and pharmaceutically acceptable salts thereof. The compounds of the invention are BDII- selective inhibitors of BET proteins, and have therapeutic potential for treating cancer, acute kidney disease, and viral infections, among other diseases.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
29.
HIGH VISUAL ACUITY, HIGH SENSITIVITY LIGHT SWITCHABLE NEURAL STIMULATOR ARRAY FOR IMPLANTABLE RETINAL PROSTHESIS
Retinal prostheses are described with visual acuity better than 20/150, and higher sensitivity, dynamic range, and FOV than the state-of-the-art. At least two different techniques are presented, the first being an optically-switched vertical single-transistor amplifier for ultrahigh photocurrent amplification, and the second being nanopatterned pillar electrodes.
Disclosed herein are vanadium active materials, methods of making the same, and energy storage devices comprising the same. The vanadium active material may be incorporated into an electrode with a graphene scaffold, the graphene scaffold having a three-dimensional network of interconnected pores, a first vanadium oxide in a first oxidation state, and a second vanadium oxide in a second oxidation state.
The present disclosure provides thermoreversible polymers, hydrogel compositions comprising the thermoreversible polymers, as well as methods of making and using the thermoreversible polymers. In some cases, the thermoreversible polymer comprises a N-isopropylacrylamide (NIPAM) co-monomer, a lower alkyl amine co-monomer and a polyethylene glycol) (PEG) comonomer.
Methods, devices, and systems for assisting individuals with communication are provided. In particular, methods, devices, and systems are provided for decoding words and sentences directly from neural activity of an individual. Cortical activity from a region of the brain involved in speech processing is recorded while an individual attempts to say or spell out words. Deep learning computational models are used to detect and classify words from the recorded brain activity. Decoding of speech from brain activity is aided by use of a language model that predicts how likely certain sequences of words are to occur. In addition, decoding of attempted non-speech motor movements from neural activity can be used to further assist communication. This neurotechnology can be used to restore communication to patients who have lost the ability to speak and has the potential to improve autonomy and quality of life.
A biocompatible gel matrix that is produced from an emulsion comprising a water-soluble material capable of forming a gel and a biocompatible hydrophobic substance is provided. In certain aspects, the biocompatible gel matrix of the present disclosure may include a plurality of microchannels and a plurality of nanochannels, wherein the plurality of microchannels and the plurality of nanochannels are not patterned microchannels and nanochannels; and a plurality of cells, wherein the cells are adjacent the plurality of microchannels and wherein a majority of the plurality of cells are within a distance of 50 microns or less from at least one of the plurality of microchannels, wherein the plurality of microchannels have a width of 5-500 microns and the plurality of nanochannels have a width of 1 nm-500 nm. Methods of using the matrix and methods of making the matrix are also provided.
A point-of-use method for identifying one or more components of an unknown drug sample includes electrochemically analyzing the unknown drug sample to obtain an electrochemical measurement, identifying the components of the unknown drug sample by inputting the electrochemical measurement into a machine learning model trained to identify the components based on the electrochemical measurement, and outputting a listing of the components. A point-of-use system for identifying one or more components of an unknown drug sample includes an electrochemical analyzer configured to receive a quantity of the unknown drug sample and conduct an electrochemical analysis to obtain an electrochemical measurement, a non-transitory storage memory storing a machine learning model trained to identify the components based on the electrochemical measurement, and one or more processors in communication with the electrochemical analyzer and configured to input the electrochemical measurement into the machine learning model and output a listing of the components.
Disclosed herein are novel serotonin 5-HT2A receptor agonists with selectivity for the 5-HT2A receptor subtype over other serotonin receptors. Some of these 5-HT2A agonists exhibit functional selectivity and preferentially activate arrestin signaling over G protein-mediated signaling. Also disclosed are pharmaceutical compositions of the compounds and methods of treating certain diseases or conditions.
The present disclosure provides methods and systems for treating affective disorders such as depression and/or anxiety and/or related disorders. Closed-loop therapy is performed with a neurostimulator that records electroencephalographic signals from neural activity associated with symptoms of a neuropsychiatric disorder and delivers electrical stimulation when pre-specified patterns of neural activity associated with a symptom are detected. Methods are also disclosed for mapping the brain of a patient to optimize placement of electrodes for detecting neural activity associated with symptoms of a neuropsychiatric disorder and to optimize placement of electrodes for delivery of electrical stimulation. Methods of monitoring and evaluating the effects of electrical stimulation on clinical symptoms and status are also provided.
In various embodiments, AAV serotypes capable of transducing skeletal muscle fibers and skeletal muscle stem cells (MuSC) with reduced off target tissue tropism are provided.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
The present disclosure provides methods and compositions for the detection, identification, classification and characterization of cancer in general and cancer types in biological material. Sequences that are not found in the human reference genome or any set of genomic tiled regions, termed nullomers, which can resurface due to mutations, serve as biomarkers and are predictive of cancer. The invention also enables the identification of cancer subtype and the stratification of patients based on sample-specific vulnerabilities guiding treatment choice. For coding nullomers it also covers their use as neoantigens. The algorithms presented hereby can be applied to biological material including biopsy, cell-free DNA samples and RNA samples.
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
39.
MULTI-CHAMBER SMART SUCTION CUP FOR TACTILE SENSING
Multi-chamber suction cups, robotic gripper elements including the same and sensing methods are provided. A multi-chamber suction cup includes a single bellows suction cup structure, and at least one internal wall defining at least two internal chambers within the single bellows suction cup structure, each of the at least two internal chambers sharing a common port for connecting to a common vacuum source, and each of the at least two internal chambers including a port for connecting to separate pressure transducers. Using the novel suction cups, novel haptic exploration methods may be implemented that can estimate the surface texture of an object and the surface normal of a curved object using sliding and palpation motion, respectively. The suction cup can also be used to localize breaks in the suction seal when the suction cup is about to detach from an object.
Described herein are bifunctional compounds, as well as pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, that function to recruit certain deubiquitinases to a target protein for modulation (e.g., stabilization) of the target protein, as well as methods of use thereof.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
In various embodiments, target phytopathogen genes are identified whose downregulation can facilitate control or prevention of an infection of a plant by a phytopathogen (e.g., a phytopathogenic fungus). In certain embodiments, double-stranded RNAs are provided to effectively downregulate the target genes.
The present invention provides a composition comprising a cannabinoid for inhibiting growth of cancer stem cells. This invention also provides methods of treating cancer comprising cancer stem cells by administering the said composition to patients in need thereof.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
Disclosed are devices placed onto an endotracheal tube to create a bend in the tube at a predetermined position. In one aspect, an endotracheal tube bending apparatus comprises a backbone portion creating an angle between a proximate end of the apparatus and a distal end of the apparatus, and a plurality of curved extensions structured to capture a tubing against the backbone portion. ln another aspect an endotracheal tube bending apparatus comprises a first prong attached to a base at a first proximate end and having a nub at a first distal end. A second prong and a third prong are each attached to the base at a second and third proximate ends and connected together via a bridge structure at a second and third distal ends. A pocket in the bridge is configured to capture the nub to hold the endotracheal tube in a bent position.
Compositions and methods for preventing and treating cardiac arrhythmia. Methods of preventing or treating arrhythmogenic right ventricular cardiomyopathy (ARVC), comprising administering to a subject in need a prophylactic or treatment effective amount of a composition comprising a plakophilin-2 (PKP2) gene. The composition further comprises an adenovirus-associated vector (AAV) to deliver the PKP-2 gene. In embodiments, the invention provides that the AAV is a cardiotropic AAV serotype and contains a cardiac-specific promoter. Method of treating a cardiovascular disease characterized by abnormal cardiac cell-cell junction complex comprising administering to a subject in need a prophylactic or treatment effective amount of a composition comprising a plakophilin-2 (PKP2) gene.
Provided herein are tetracyclic heterocyclic compounds which can be useful for methods of treating a disease or for increasing neural plasticity. The compounds can also be useful for increasing dendritic spine density.
A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
Disclosed herein are compositions of retroviruses and methods of using the same for gene delivery to a hematopoietic stem cell (HSC), wherein the retroviruses comprise a viral envelope protein comprising at least one mutation that diminishes its native function, a non- viral membrane -bound protein comprising a membrane-bound domain and an extracellular targeting domain.
Disclosed herein are methods of electrochemically enhanced amine-based CO2 capture and systems for performing the methods of amine-based CO2 capture. The present methods and systems advantageously may be carried out at ambient temperatures and allow for reusing the amine through multiple cycles.
B01D 53/32 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
C25B 9/17 - Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof
Systems and methods for conditioning respiratory muscles in a patient are described. In some variations, a method for conditioning respiratory muscles in a patient may include administering a stimulation signal to a thoracic spinal cord region of a patient, where the stimulation signal is effective to augment and/or sustain activation of one or more respiratory muscles in the patient, thereby maintaining strength of the one or more respiratory muscles. In some variations, the method includes administering the stimulation signa in response to detecting an inspiratory phase of the patient, such as via one or more sensors.
Provided herein, inter alia, are methods and compounds for treating and preventing neural cell death, e.g., retinal ganglion cell death. Also provided herein, inter alia, are methods and compounds for treating and preventing nerve degeneration. The methods and compounds provided herein may treat or prevent glaucoma.
Provided herein, inter alia, are compositions including viruses and nucleic acids having promoters capable of expressing multiple heterologous nucleic acids. The compositions are particularly useful for delivering and expressing heterologous nucleic acids in neurons. With respect to the nervous system, neural tissue, and neurons, the compositions listed herein are contemplated to be effective for treatment of retinal neurodegenerative diseases.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
51.
METHODS AND AGENTS FOR MODULATING ADOPTIVE IMMUNOTHERAPY
This disclosure relates to methods and agents for modulating adoptive immunotherapy to enable bioengineered immune cells to utilize xenobiotic fuel, e.g., in a low glucose environment. The immune cells may be used, e.g., for treatment of a tumor or cancer, such as part of a therapeutic treatment of cancer or for treatment of a bacterial, fungal, or viral infection, alone or in combination with a low glucose (e.g., ketogenic) diet. They may also be used to treat a tumor, a cancer, an infection, an autoimmune disease, or an inflammatory or neuroinflammatory disease or condition in a patient on a low glucose diet. The immune cells may be used in combination with a scaffold or platform or with a microparticle or nanoparticle for localization of treatment or xenobiotic nutrients or for controlled release, as well as for other therapeutic uses.
The present disclosure relates to targeted degradation platform technology. For example, the present disclosure relates to bispecific binding agents for degrading endogenous proteins, whether membrane-associated or soluble, using the lysosome pathway. The disclosure also provides methods useful for producing such agents, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various disorders.
Microglia/monocytes exist within a 'niche' which limits the total number of microglia/monocytes/macrophages that reside within a mammalian central nervous system (CNS). Therefore, methods are needed that can help therapeutically modify microglia, monocytes, and macrophages or the cells that give rise to them to compete with endogenous microglia and partially or completely occupy the CNS niche. The present disclosure features therapeutic microglia, monocytes, or macrophages that have a selective advantage in comparison to endogenous brain resident microglia in their response to CSF1 R inhibitors. Specifically, therapeutic cells developed in the present disclosure do not die at a given dose of CSF1 R inhibitor that is sufficient to kill endogenous microglia. The therapeutic cells described herein can be used to treat neurological diseases.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The invention provides, for the first time, cells that express truncated or modified Fc Receptor proteins (e.g. CD16t, CD32t, or CD64t) to evade antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). The cells may be pluripotent cells, including hypoimmune pluripotent cells (HIP) or ABO blood type O Rhesus Factor negative HIP cells (HIPO-), that express a truncated or modified Fc Receptor. The invention encompasses cells derived from the pluripotent cells as well as primary cells. The cells may also be differentiated cells, including chimeric antigen receptor (CAR) cells, T cells, natural killer (NK) cells, endothelial cells, dopaminergic neurons, neuroglial cells, pancreatic islet cells, pancreatic beta cells, thyroid cells, fibroblasts, hepatocytes, cardiomyocytes, or retinal pigment endothelium cells.
The present disclosure relates generally to the field of immunology, and particularly relates to hybrid chimeric antigen receptors designed to combine fast time-scale intracellular signal transduction and long time-scale transcription regulation. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various health conditions or diseases, such as cancers.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure generally relates to, among other things, a new class of receptors engineered to modulate transcriptional regulation in a ligand-dependent manner. In particular, the new receptors contain a heterologous stop-transfer-sequence and a ?-secretase cleavable transmembrane domain. The disclosure also provides compositions and methods useful for producing such receptors, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various diseases such as cancers.
Provided are methods for modification of amino acid sequence and increasing levels of expression of ApoA-I Binding Protein to treat: a neuropathic pain, a CNS inflammation, an allodynia, a post nerve injury pain, a post-surgical pain, a chemotherapeutic-induced peripheral neuropathy, a neurodegeneration, including for example, a neurodegenerative disease or condition such as Alzheimer's disease, a hyperalgesia, primary headaches such as migraines and cluster headaches, glaucoma or other inflammatory diseases of the eye, lung inflammation, asthma, HIV infection, vascular inflammation, atherosclerosis and cardiovascular disease. Provided are methods comprising administering pharmaceutical compositions comprising a recombinantly modified APOA1BP polypeptide to treat a neuropathic pain, an allodynia, a hyperalgesia, a neurodegenerative disease, a primary headache such as a migraine, glaucoma, lung inflammation and asthma, acute respiratory distress syndrome (ARDS), sepsis, viral infection, including influenza, coronavirus (for example, COVID-19) or HIV infection, or its comorbidities, and/or vascular inflammation, atherosclerosis and cardiovascular disease.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
A61P 25/00 - Drugs for disorders of the nervous system
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
Mchugh, Tara H.
Bilbao-Sainz, Christina
Powell-Palm, Matthew J.
Rubinsky, Boris
Abstract
Fruits and vegetables are impregnated with ascorbic acid impregnation fluids during an isochoric freezing process. The ascorbic acid impregnation fluids are infused into the void pores of fruits and vegetables, without destroying cellular tissue. The infusion of ascorbic acid can prevent browning of fruits and vegetable products, increase the products' vitamin C content, and inhibit microbial growth.
A23L 3/3454 - Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
A23L 29/00 - Foods or foodstuffs containing additives; Preparation or treatment thereof
A23P 30/00 - Shaping or working of foodstuffs characterised by the process or apparatus
A microfluidic device uses hydrodynamic shear forces on a sample to improve the speed and efficiency of tissue digestion is disclosed. The microfluidic channels are designed to apply hydrodynamic shear forces at discrete locations on tissue specimens up to 1 cm in length and 1 mm in diameter, thereby accelerating digestion through hydrodynamic shear forces and improved enzyme-tissue contact. The microfluidic digestion device can eliminate or reduce the need to mince tissue samples with a scalpel, while reducing sample processing time and preserving cell viability. Another advantage is that downstream microfluidic operations could be integrated to enable advanced cell processing and analysis capabilities. The device may be used in research and clinical settings to promote single cell-based analysis technologies, as well as to isolate primary, progenitor, and stem cells for use in the fields of tissue engineering and regenerative medicine.
The present disclosure provides methods and compositions for increasing resistance of plants to a disease caused by infection with bacteria of a Liberibacter species.
A unibody transtibial prosthetic device includes a socket personalized for a specific patient's residual limb. A pylon extends from the socket, the pylon being a unitary polymer structure of interconnected elongated supports having open spaces therebetween. The device also includes a foot-ankle complex, the foot-ankle complex being a unitary polymer extending from the pylon, the foot and ankle unitary structure being shaped to provide multi-axial dynamic flex to enable dorsiflexion, plantar flexion, inversion and eversion motion for smooth symmetric gait performance and energy capture and return. The socket, pylon and foot-ankle complex are portions of a unibody.
Methods, systems, and devices are disclosed for collecting and transferring naturally-produced sweat containing an analyte to a biosensor and/or biofuel cell to estimate a concentration of the analyte corresponding to the analyte's concentration in blood and/or for producing electricity. In some aspects, a device includes a substrate, a plurality of electrodes disposed on the substrate and operable to detect an analyte in naturally-produced sweat of an individual, and a sweat permeation layer including a hydrogel, wherein the sweat permeation layer is in contact with the plurality of electrodes and configured to transfer the sweat containing the analyte through the sweat permeation layer to reach the plurality of electrodes for detection and/or energy harvesting.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 10/00 - Other methods or instruments for diagnosis, e.g. for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
64.
LARYNGOSCOPY APPARATUS HAVING MEANS FOR CLEARING MATERIAL FROM ITS VIEWING WINDOW
In one embodiment, a laryngoscopy apparatus includes a handle configured for gripping by an operator, a blade extending from the handle configured for insertion into the trachea of a patient, a clear viewing window provided on the blade that enables a patient's airway to be viewed, and means for clearing material from the viewing window that could obscure the view of the airway.
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with illuminating arrangements
In alternative embodiments, provided are methods for treating and ameliorating a cancer, or recurrence of a cancer such as acute myeloid leukemia (AML) comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S?FD?895 (or rebecsinib) and second drug such as an ATP-competitive protein tyrosine kinase inhibitor such as dasatinib. In alternative embodiments, provided are methods for the in vivo inhibition of myeloproliferative neoplasm (MPN) or AML stem cell propagation comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S?FD?895 and second drug. In alternative embodiments, provided are methods for the in vivo inhibition pre-leukemia stem cell (pre?LSC) transformation into leukemia stem cells (LSCs) comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S?FD?895 and second drug.
Provided herein are complositions and methods for treating neuroendocrine cancer and preventing or treating metastasis originating from a neuroendocrine cancer.
A system includes a wearable device disposed on a person, the wearable device has a plurality of sensors, each of which is configured to output a sound waveform in response to sounds generated by physiological activity of the person. The system also includes a processing device coupled to the plurality of sensors and configured to process and store the sound waveforms as sound files. The system also includes a sound output device coupled to the processing device. The sound output device is configured to output the sound files to mimic in utero sounds.
A61M 21/00 - Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
A61M 21/02 - Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
Systems, compositions, and methods for target site-specific insertion of a transgene of interest to a subject genome are provided. Systems and methods that facilitate primed reverse transcription (TPRT) mediated by retroelement derived reverse transcriptase (RTs) site-specific transgene insertion are also provided.
The present disclosure provides compositions and methods for prime editing with improved editing efficiency and/or reduced indel formation by inhibiting the DNA mismatch repair path way while conducting prime editing of a target site. Accordingly, the present disclosure provides a method for editing a nucleic acid molecule by prime editing that involves contacting a nucleic acid molecule with a prime editor, a pegRNA, and an inhibitor of the DNA mismatch repair pathway, thereby installing one or more modifications to the nucleic acid molecule at a target site with increased editing efficiency and/or lower indel formation. The present disclosure further provides polynucleotides for editing a DNA target site by prime editing comprising a nucleic acid sequence encoding a napDNAbp, a polymerase, and an inhibitor of the DNA mismatch repair pathway, wherein the napDNAbp and polymerase is capable in the presence of a pegRNA of installing one or more modifications in the DNA target site with increased editing efficiency and/or lower indel formation. The disclosure further provides, vectors, cells, and kits comprising the compositions and polynucleotides of the disclosure. The present disclosure also provides compositions and methods for prime editing with improved editing efficiency and/or reduced indel formation with modified prime editor fusion proteins. The disclosure further provides, vectors, cells, and kits comprising the compositions and polynucleotides of the disclosure.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Disclosed herein are methods of treating cancer. Some such methods include administration of a first anti-cancer agent that increases CD46 expression on the surface of a cancer cell. Some embodiments include administration of a second anti-cancer agent that binds CD46. The second anti-cancer agent may include an immunoconjugate comprising a CD46 binding domain and effector agent.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
72.
ENGINEERED GAMMA DELTA T CELLS AND METHODS OF MAKING AND USING THEREOF
Aspects of the present disclosure relate to methods and compositions related to the preparation of immune cells, including engineered T cells comprising at least one exogenous ?d T cell receptor, for example one that is selected to target a specific disease or pathogen (e.g., cancer or COVID-19). The T cells may be produced from human hematopoietic stem/progenitor cells and are suitable for allogeneic cellular therapy because they do not induce graft-versus-host disease (GvHD) and resist host immune allorejection. Consequently, such cells are suitable for off-the-shelf use in clinical therapy.
The present disclosure describes a high-throughput methodology for rapid and highly personalized screenings to identify efficacious anti-tumor immunotherapy regiments. In one embodiment, therapeutic agents or a combination thereof are screened by co-culturing tumor shaped organoid extrudates with a population of immune cells taken from the same patient. Reduced tumor cell functions or increased immune cell functions in the presence of the therapeutic agents or combination thereof would identify the therapeutic agents or combination thereof for treating the tumor in the patient.
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
In one embodiment, the present disclosure provides a tissue culture well insert for use with a multi-wells tissue culture plate. The cylindrical well insert is configured to be inserted into the tissue culture wells, wherein the well insert comprises a carrier or platform section on which liver cells or other cells are deposited, and the carrier or platform section is positioned in the tissue culture wells so as to be suspended off the bottom of the tissue culture wells. The well insert is useful for co-culturing multiple cell types to create in vitro biological systems. One specific application is high-throughput anti-tumor drug screening in which the liver cells or other cells carried by the carrier or platform section of the insert are co-cultured with tumor organoids deposited or bioprinted to the bottom of the tissue culture well.
The invention provides cells that have an increased Signal Regulatory Protein Alpha (SIRP?? ) engagement function (SIRP? engager cells) that resist innate immunity when transplanted into a subject when compared to a parental cell having an unmodified SIRP? engagement function. The SIRP? engager cells lack an intact CD47 cytoplasmic signalling function. In some embodiments, the SIRP? engager cells are hypoimmune cells. In other embodiments, the SIRP? engager cells are differentiated somatic cells. In other embodiments, the SIRP? engager cells are hypoimmune pluripotent (HIP) cells. In further embodiments, the HIP cells are blood type O (HIPO), Rhesus factor (Rh) negative (HIP-) or both type O and Rh- (HIPO-). In other embodiments, the SIRP? engager cells have been derived or differentiated from HIP, HIP-, or HIPO- cells. In other embodiments, the SIRP? engager cells comprise an antibody Fc receptor to protect against antibody dependent cellular cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC). In other embodiments, the SIRP? engager cells evade ADCC or CDC via elevated cell surface CD16, CD32, or CD64 expression.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
Sugahara, Kazuki
Lowy, Andrew M.
Abstract
The invention described relates to the newly discovered ability of tumor internalizing arginylglycylaspartic acid (iRGD) peptides to alter the immune cell landscape in pancreatic ductal adenocarcinoma (PDAC) and other cancers. The iRGD peptides sensitize the cancer to immune checkpoint inhibitors, for example anti-PD-L1, anti-PD-L1. anti-PD-1, and anti-CTLA4 monoclonal antibodies to specifically deplete Tregs within the tumor, resulting in expansion of intratumoral CD8+ T cells (effector cells). This provides methods of treating cancers such as PDAC, preferably in synergistic combination with chemotherapy and immunotherapy, which leads to reduced tumor burden and prolonged survival.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure provides methods and related compositions that incorporate a molecularly targeted approach via the integrin subtype avß6 using Peptide Receptor Radionuclide Therapy (PRRT) and a theranostic approach.
C07D 225/02 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
C07D 295/04 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
C07D 295/08 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic System
78.
PHOTO RECHARGEABLE ELECTROCHEMICAL ENERGY STORAGE DEVICE
A photo rechargeable electrochemical energy storage device, a power generation device, and a method for fabricating the photo rechargeable electrochemical energy storage device in a mostly unrestricted atmospheric environment are disclosed. The power generation device including a rechargeable electrochemical energy storage device including a photoanode arranged beneath a transparent electrode, the photoanode comprising an oxide of titanium; and a micro-power conversion controller configured to control delivery of power under load, and recharge the rechargeable electrochemical energy storage device when not under rated load and when the transparent electrode is exposed to sufficient light and/or grid power is available.
Systems and methods for tree census collection are provided. Many embodiments provide improvements to tree modeling, including dimensions of tree crowns, which provides greater accuracy in tree modeling. Furthermore, the improvements to tree modeling provide in-situ datasets to ground truth high resolution satellite imagery, LiDAR, and other remotely sensed products and models. The method may also be used to model and ground truth other remotely sensed phenomena having irregular shapes, such as nebula, vapor plumes, volcanic eruptions, cloud cover, sea cover, on Earth, other planetary bodies, or elsewhere in space, and for improved modeling of remotely sensed physical phenomena from data collected from satellites, embedded sensors, telescopes and other astrophotography systems.
Provided and described are bacterial mechanosensory polypeptide and encoding polynucleotide products and compositions thereof, methods of expressing such polypeptides and polynucleotides in a cell type of interest, and methods of inducing and/or modifying the activity or function of various types of cells, including neurons, which express exogenous bacterial mechanosensory polypeptides, using ultrasound.
C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
G01N 29/00 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
81.
COMPOSITIONS AND METHODS FOR TREATING CELIAC SPRUE DISEASE
The present disclosure is directed to polypeptides capable of cleaving gluten proteins, e.g., gliadins, nucleic acid molecules encoding the same, pharmaceutical compositions comprising the same, and methods of use thereof for treating celiac sprue disease and/or non-celiac gluten sensitivity (NCGS).
Disclosed herein are pharmaceutical compositions comprising an azobenzene photoswitch compound and an alkylated cyclodextrin. Such compositions may be administered to the eye to treat a variety of retina disorders.
A61K 31/655 - Azo (—N=N—), diazo (=N2), azoxy (N—O—N or N(=O)—N), azido (—N3) or diazoamino (—N=N—N) compounds
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
The present invention provides compositions and methods for treating a disease involving inappropriate or excessive cell proliferation or for treating an inflammatory condition or an autoimmune disease by inhibiting MYC activity in cells such as MYC-dependent cancer cells.
Compositions for treating an ischemic condition in a subject may include hexosamine D-mannosamine (ManN). Methods may include administering to the subject in need thereof an effective amount of ManN. The administration may be effective to promote endothelial cell proliferation and angiogenesis in the subject. The subject may be in need of induced angiogenesis due to an ischemic condition caused by disease or trauma. Compositions for inhibiting protein glycosylation in a cell may include ManN. Methods for inhibiting protein glycosylation in a cell may include administering to the cell an effective amount of ManN.
C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
85.
COMPUTATIONAL CARDIAC DEPOLARIZATION AND REPOLARIZATION SIMULATION LIBRARY MAPPING FOR NON-INVASIVE ARRHYTHMIA RISK STRATIFICATION
A non-invasive method for cardiac arrhythmia risk stratification may include identifying, based at least on an electrical recording of a patient, a cardiac depolarization simulation and a cardiac repolarization simulation corresponding to an electrical recording of a patient. One or more regions of increased spatial repolarization gradient in which a first area of a myocardium of the patient exhibits a first repolarization rate that differs from a second repolarization rate of a second area of the myocardium by an amount then divided by the spatial distance between the two regions, by a threshold value may be determined based on the cardiac depolarization simulation and the cardiac repolarization simulation. A risk of cardiac arrhythmia for the patient may be determined based a magnitude of the increased spatial repolarization gradient. Moreover, a treatment plan for the patient may be determined based on the magnitude and/or location of the increased spatial repolarization gradient.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
In certain embodiments a platform technology for the facilitating immune therapy in the treatement of cancer is provided. In certain embodiments nanocarriers are provided that facilitate delivery of an IDO inhibitor in conjunction with an inducer of cell death (ICD-inducer). In certain embodiments the IDO inhibitor is conjugated to a component of a lipid bilayer forming a nanovesicle. In still another embodiment, methods and compositions are provided where an ICD-inducing agent (e.g., doxorubicin, oxaliplatin, mitoxantrone etc.) and an IDO pathway inhibitor (e.g., an IDO inhibitor -prodrug) are integrated into a nanocarrier (e.g. a lipid-bilayer (LB) -coated nanoparticle), that allows systemic delivery to orthotopic pancreatic cancer site.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
The disclosure provides for compounds and compositions comprising universal endosomal escape domains, and applications thereof, including for delivering macromolecules into cells.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
88.
INTEGRATED MICROFLUIDIC SYSTEM FOR THE PROCESSING OF TISSUES INTO CELLULAR SUSPENSIONS
A microfluidic system for processing a tissue sample includes a microfluidic digestion device having an outlet fluidically connected to an inlet of a dissociation/filter device. The microfluidic digestion device includes an inlet and an outlet and a tissue chamber that connects to plurality of upstream fluidic channels and a plurality of downstream fluidic channels. The microfluidic dissociation/filter device includes an inlet, a first outlet, a second outlet, and a plurality of furcating dissociation channels having a plurality of expansion and constriction regions disposed along a length thereof, wherein one or more filters are disposed in a flow path downstream of the plurality of furcating dissociation channels. Pumps are provided to pump buffer and/or enzyme-containing fluid through the digestion device and dissociation/filter device. Tissue is initially processed in the digestion device and then passes into the dissociation/filter device.
A61B 10/00 - Other methods or instruments for diagnosis, e.g. for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
C12M 1/00 - Apparatus for enzymology or microbiology
89.
GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS
New fluorescent biosensors are provided for use in methods of detecting a ligand-induced hallucinogenic conformational change of a G Protein-Coupled Receptor (GPCR), detecting a hallucinogenic compound, detecting a non-hallucinogenic antidepressant compound, measuring the hallucinogenic potential of a compound, measuring the antipsychotic potential of a compound, and suitable kits thereof.
A hybrid microcapsule including: a shell that comprises one or more biocompatible material, exosomes contained within the microcapsule and one or more therapeutic cells encapsulated within the microcapsule, wherein the therapeutic cells are capable of releasing one or more therapeutic agent(s). Also disclosed are methods of making the hybrid microcapsule and methods of treating a subject including administering the hybrid microcapsule to the subject, wherein the therapeutic cells contained within the hybrid microcapsule release the one or more therapeutic agent(s) to the subject and wherein the hybrid microcapsule releases the exosomes to effectively attenuate an immune-based foreign body response (FBR).
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C12N 15/90 - Stable introduction of foreign DNA into chromosome
92.
COMPOSITIONS AND METHODS FOR MODULATING TCF4 GENE EXPRESSION AND TREATING PITT HOPKINS SYNDROME
The disclosure provides recombinant cassettes and vectors encoding TCF4 polypeptides and their use in treating neurological or neurodevelopmental disease and disorders.
Provided are methods for identifying an RNA nucleobase that interacts with an RNA binding protein (RBP) including (a) crosslinking the RNA binding protein to an RNA fragment in a biological sample; (b) detecting an RNA-RBP complex, wherein the RNA-RBP complex comprises the RNA fragment bound by the RNA binding protein; (c) isolating the RNA fragment of the RNA-RBP complex; and (d) profiling the isolated RNA fragment bound by the RNA binding protein, thereby identifying the RNA nucleobase of the RNA fragment that interacts with the RNA binding protein.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Methods for the detection of metastatic cancer and determination of its tissue of origin on the basis of non-human, microbial nucleic acids in tissue or blood.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
95.
CHARGED MEMBRANES INCORPORATED WITH POROUS POLYMER FRAMEWORKS
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
B01D 71/82 - Macromolecular material not specifically provided for in a single one of groups characterised by the presence of specified groups, e.g. introduced by chemical after-treatment
Devices and methods that use magnetic forces to modulate bone growth are disclosed. In particular, embodiments of the presently disclosed technology apply the Heuter-Volkmann law which states that when compressive forces are exerted across a growth plate, new bone growth is inhibited, and when tensile forces are exerted across a growth plate, new bone growth is stimulated. Accordingly, embodiments use attractive forces and repulsive forces between magnets to exert compressive and tensile forces across the growth plates of a patient, thus modulating new bone growth in the patient.
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
B01D 71/82 - Macromolecular material not specifically provided for in a single one of groups characterised by the presence of specified groups, e.g. introduced by chemical after-treatment
The present disclosure provides compositions and methods of using one or more of the metabolites spermidine, palmitoylethanolamide (PEA), oleoylethanolamide (OEA), and 1-methylnicotinamide (1-MNA) to induce an anti-inflammatory, anti-oxidant, and/or immuno-modulatory effect in a subject. The compositions and methods described herein can enhance biochemical functionalities relevant to overall health and disease progression, promote longevity and healthspan, and/or delay or inhibit the cellular aging process in the subject.
A61K 31/132 - Amines, e.g. amantadine having two or more amino groups, e.g. spermidine, putrescine
A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
A61K 31/455 - Nicotinic acid, i.e. niacin; Derivatives thereof, e.g. esters, amides
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
An apparatus for a lateral flow nucleic acid assay with an integrated pore-based detector, which has the potential to detect pathogens, both microbial and viral, in aqueous samples in approximately 5 minutes or less without nucleic acid amplification or optical components. The detector is based on an electromechanical signal transduction mechanism that enables low-cost detection of DNA/RNA at ultralow concentrations (down to about 10 M to about 19 M). The scheme relies on the use of charge-neutral peptide nucleic acid (PNA) capture probe conjugated to polystyrene beads. The PNA-beads acquire substantial negative charge upon capture of target pathogenic DNA/RNA and become mobile in an electric field. Upon application of a bias voltage of around 1 V to 2 V, the PNA-beads with hybridized target are directed electrophoretically to a smaller diameter pore. Subsequent pore blockage results in a strong, sustained drop in measured ionic current through the pore.
The present disclosure relates to compounds that increase sarcospan expression. The disclosure further relates to methods of treating a disease related to diminution or dysfunction of a dystrophin-related complex in a subject in need thereof.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 215/16 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
patents
